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Other names: DD3; HA1753; HAKRB; HAKRe; 




1170 bp mRNA; transcript has been detected in brain, 




323 amino acids, molecular weight 37 kDa. 
Expression 
Activated macrophage, malignant prostate epithelium, 
normal mammary epithelium, mature blood vessel. 
Localisation 
Mainly in cytoplasm. 
Function 
AKR1C3 metabolizes various androgen metabolites 
including 5a-dihydrotestosterone to 5a-androstane-
3a,17b-diol, Delta4-androstene-3,17-dione to 
testosterone, androstanedione to 5a-
dihydrotestosterone, androsterone to 5a-androstane-
3a,17b-diol. 
AKR1C3 is also involved in estrogen metabolism 
converting estrone to 17b-estradiol as well as 
progesterone metabolism converting prostaglandin D2 
to 9a,11b-prostaglandin F2a. 
AKR1C3 has the capability of regulating the trans-
activation of various nuclear receptors including 
androgen receptor, estrogen receptor, and peroxisome 
proliferator activated receptor (PPARG) by regulating 
the ligand availability for the nuclear receptors. 
Homology 
A member of the of AKR1C family proteins; AKR1C1, 
AKR1C2, AKR1C3, AKR1C4 in human, and AKR1C9 
in rat. 
Mutations 
Note: Mutation of AKR1C3 has not been identified. 
Implicated in 
Various cancers 
Note: Elevated levels of AKR1C3 expression are 
implicated in leukemia cell differentiation, prostate 
cancer (in both androgen-dependent and androgen-
independent prostate cancer), and endometrial cancer. 
Expression of AKR1C3 was detected in a patient with 
myelodysplastic syndrome (MDS, refractory anemia) 
with progression to acute myelogenous leukemia. 
Overexpression of AKR1C3 in a human promyelocytic 
leukemia cell line, HL-60, rendered cells more resistant 
to all-trans retinoic acid (ATRA) and 1a,25-
dihydroxyvitamin D3 induced cell differentiation. 
Prostate cancer 
Disease 
Immunohistochemical staining of human prostate 
tissues detected negative or low levels of AKR1C3 
expression in normal prostate epithelial cells. Strong 
positive AKR1C3 immunoreactivity was demonstrated 
in primary and androgen-independent prostate cancers. 
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Variable increases in AKR1C3 expression were also 
demonstrated in non-neoplastic changes in the prostate 




Quantitative transcriptosome analysis using real-time 
polymerase chain reaction, AKR1C3 mRNA 
expression was shown to be elevated in endometrial 
cancer versus adjacent normal endometrium. 
Breast tumor 
Disease 
Expression of AKR1C3 mRNA was reduced in breast 
tumor as compared to adjacent normal breast tissue. 
Immunohistochemstry revealed that the ductal 
epithelial cells and stromal cells of the breast express 
AKR1C3. In myoepithelial cells of the breast, 
immunoreactive AKR1C3 was absent in normal 
tissues, whereas strong AKR1C3 staining was apparent 
in cells surrounding the neoplastic epithelium of ductal 
carcinoma in situ. 
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